Leukemia

Article	Citations
Quantifying measurable residual disease correctly	2366
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	2081
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	182
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	173
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	159
Cohesin mutations in acute myeloid leukemia	143
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	141
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	129
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	125
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	120
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	120
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	105
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	103
Clonal medicine targeting DNA damage response eradicates leukemia	99
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age	94
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	93
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	92
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	91
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	88
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	87
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	82
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders	81
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	81
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	77
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	76

An MDM2 degrader for treatment of acute leukemias	73
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	72
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	72
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	69
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia	69
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial	69
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	68
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	66
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	65
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	64
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	64
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	64
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	64
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	64
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	63
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	62
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	61
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	60
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	59
Real life evaluation of AlphaMissense predictions in hematological malignancies	58
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	57
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	55
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	54
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation	54
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia	54
RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data	53
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	51
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	50
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	50
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signaling	49
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia	48
Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development	48
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies	48
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis	47
Publisher Correction: Rolf Neth (October 6, 1926–March 17, 2020)	47
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors	47
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG	46
Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	46
Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia	45
Combining lenalidomide with erythropoiesis stimulating agents: a party of one	45
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression	45
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia	45
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL	45
Measurable residual disease (MRD)-testing in haematological and solid cancers	45
Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial	44
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells	44
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis	44
PHF6 suppresses self-renewal of leukemic stem cells in AML	44
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials	43
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma	43

Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia	43
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy	41
Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment	41
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia	41
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials	41
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia	41
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML	41
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	40
METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	40
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	40
Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo	39
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib	39
Insufficiency of FZR1 disturbs HSC quiescence by inhibiting ubiquitin-dependent degradation of RUNX1 in aplastic anemia	39
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia	39
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose	38
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL	38
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia	38
Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia	38
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study	38
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms	37
Second versus first wave of COVID-19 in patients with MPN	37
New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery	36
Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks	36
Functions of the native NPM1 protein and its leukemic mutant	35
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis	35
A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome	35
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm	35
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation	34
CLL cell-derived exosomes alter the immune and hematopoietic systems	34
Emerging T-cell lymphomas after CAR T-cell therapy	34
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort	34
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	33
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study	33
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients	33
Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study	32
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms	32
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib	32
Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells	31
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia	31
Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	31
How should we interpret conclusions of TKI-stopping studies	31
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases	31
What is radiation-induced acute myeloid leukaemia/can it be accurately identified?	30
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis	30
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD	30
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies	30
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia	30
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia	30
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis	30
Immunogenetics in hematopathology and hematology: why a common language is important	30
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment	30
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics	29
Relationship among three common hematological premalignant conditions	29
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma	29
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML	29
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia	29
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms	29
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis	29
Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients	28
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma	28
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)	28
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation	28
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies	28
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202	28
Correction: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways	28
How fast does leukemia progress?	27
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress	27
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia	27
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis	27
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow	27
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?	27
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia	26
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML	26
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma	26
S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist	26
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	26
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	26
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction	26
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study	26
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia	26

Leukemogenesis occurs in a microenvironment enriched by extracellular microvesicles/exosomes: recent discoveries and questions to be answered	26
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma	26
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma	26
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia	25
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	25
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach	25
Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study	25
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes	25
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study	25
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	24
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia	24
Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946–October 8, 2021)	24
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma	24
Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia	24
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment	24
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)	23
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation	23
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations	23
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses	23
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19	23
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period	23
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression	23
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms	23
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma	23
Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma	22
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease	22
Recommendations for future extensions to the HGNC gene fusion nomenclature	22
Survival with chronic myeloid leukaemia after failing milestones	22
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures	22
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	22
Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy	22
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia	22
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT	22
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results	22
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice	22
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis	22
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation	22
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia	22
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data	21
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia	21
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia	21
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	21
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In	21
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study	21
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given	21
Skin lesions, arthritis, chondritis, and cytopenias	21
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia	21
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	21
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?	21
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease	21
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase	20
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis	20
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group	20
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia	20
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies	20
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition	20
Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia	20
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML	20
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations	20
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working p	20
Acute myeloid leukemia: does sex matter?	20
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma	20
Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia	20
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma	20
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma	20
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients	20
RBC distribution width predicts thrombosis risk in polycythemia vera	19
P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression	19
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)	19
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia	19
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis	19
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance	19
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis	19
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia	19
Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age	19
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation	19
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells	18
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia	18
Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients	18
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance	18
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia	18
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study	18
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma	18
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	18
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease	18
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL	18
Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression	18
A DNA methylation database of human and mouse hematological malignancy cell lines	18
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	18
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis	18
Germline CHEK2 mutations in patients with myeloid neoplasms	17
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	17
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes	17
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update	17
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)	17